Crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets based on hydroxypropyl methylcellulose

Journal of Controlled Release

Volumn 54, Issue 1, 1998, Pages 69-85

  Katzhendler, Ifat ^a   Azoury, Reuven ^b   Friedman, Michael ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Radiopharmaceutical Division   (Israel)

Author keywords

Carbamazepine; Crystallinity; Differential scanning calorimetry; Hydroxypropyl methylcellulose; Scanning electron microscopy; Sustained release; X ray diffraction

Indexed keywords

CARBAMAZEPINE; HYDROXYPROPYLMETHYLCELLULOSE; METHYLCELLULOSE;

AQUEOUS SOLUTION; ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG TRANSFORMATION; EPILEPSY; HYDROGEN BOND; MATRIX TABLET; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUSTAINED RELEASE PREPARATION; TRIGEMINUS NEURALGIA; X RAY POWDER DIFFRACTION;

EID: 0031750464     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(98)00002-9     Document Type: Article

References (33)

1. R.S. Porter, Clinical efficacy and use of antiepileptic drugs, in: D.M. Woodbury, J.K. Penry, C.E. Pippenger (Eds.), Antiepileptic Drugs, Raven Press, New York, 1982, pp. 167-175.
2. J.M. Killian, G.H. From, Carbamazepine in the treatment of neuralgia: use and side effects, Arch. Neurol. 19 (1968) 129-136.
3. H. Pohlmann, Dh. Gulde, R. Jahn, S. Pfeiffer, Polymorphic, Teilchengrosse and Blutspiegelwerte von Carbamazepin, Pharmazie 30 (1975) 709-711.
4. F.U. Krahn, J.B. Mielck, Relations between several polymorphic forms and the dihydrate of carbamazepine, Pharm. Acta Helv. 62 (1987) 247-254.
5. 2O, Cryst. Res. Technol. 21 (1986) 1463-1468.
6. United States Pharmacopeia 22nd Rev., US Pharmacopeia Convention, Rockville, MD, 1989, pp. 222, 1813.
7. E. Laine, V. Tauminen, V. Ilvessalo et al., Formation of dihydrate from carbamazepine anhydrate in aqueous solution, Int. J. Pharm. 20 (1984) 307-314.
8. W.W. Young, R. Suryanarayanan, Kinetics of transition of anhydrous carbamazepine to carbamazepine dihydrate in aqueous suspensions, J. Pharm. Sci. 8 (1991) 496-500.
9. K. Kahela, R. Aaltonen, E. Lewing et al., Pharmacokinetics and dissolution of two crystalline forms of carbamazepine, Int. J. Pharm. 14 (1983) 103-112.
10. C.C. Evans, Whiskers, Mills and Boon, London, 1972.
11. M.M.J. Lowes, M.R. Caira, A.P. Lotter et al., Physico-chemical properties and X-ray structural studies of the trigonal polymorph of carbamazepine, J. Pharm. Sci. 76 (1987) 744-752.
12. F.U. Krahn, J.B. Mielick, Effect of type and extent of crystalline order on chemical and physical stability of carbamazepine, Int. J. Pharm. 53 (1989) 25-34.
13. Y. Matsuda, R.A. Kazawa, R. Teraoka, M. Otsuka, Pharmaceutical evaluation of carbamazepine modifications: comparative study of photostability of carbamazepine polymorphs by using fourier-transformed reflection-absorption infrared spectroscopy and calorimetric measurements, J. Pharm. Pharmacol. 46 (1994) 162-167.
14. R.J. Behme, D. Brooke, Heat of fusion measurements of low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis, J. Pharm. Sci. 80 (1991) 986-990.
15. L.E. McMahon, P. Timmins, A.C. Williams et al., Characterization of dihydrates prepared from carbamazepine polymorphs, J. Pharm. Sci. 85 (1996) 1064-1069.
16. P. Giunchedi, U. Conte, A. LaManna, Carbamazepine modified release dosage forms, Drug Dev. Ind. Pharm. 17 (1991) 1753-1764.
17. P. Giunchedi, L. Maggi, U. Conte et al., Linear extended release of water-insoluble drug, carbamazepine from erodible matrices, Int. J. Pharm. 94 (1993) 15-22.
18. J.K. Haleblian, Characterization of habits and crystalline modification of solids and their pharmaceutical application, J. Pharm. Sci. 65 (1975) 1269-1288.
19. S. Byrn, R. Pfeiffer, M. Ganey et al., Pharmaceutical solids: a strategic approach to regulatory considerations, Pharm. Res. 12 (1995) 945-954.
20. J. Heller, R. Baker, R. Gale, O. Rodin, Controlled drug release by polymer dissolution. I. Partial ester of maleic anhydride copolymers - properties and theory, J. Appl. Polym. Sci. 22 (1978) 1991-2009.
21. J. Heller, Controlled release of biologically active compounds from bioerodible polymers, Biomaterials 1 (1980) 51-57.
22. I. Katzhendler, A. Hoffman, A. Goldberger, M. Friedman, Modeling drug release from erodible tablets, J. Pharm. Sci. 86 (1997) 110-115.
23. K. Kaneniwa, T. Yamaguchi, N. Watari, M. Otsuka, Hygroscopicity of carbamazepine crystalline powders, Yakugaku Zasshi 104 (1984) 184-190.
24. R. Boistelle, Impurity effects in crystal growth from solution, in: B. Mutaftschiev (Ed.), Interfacial Aspects of Phase Transformation, D. Riedel, 1982, pp. 621-638.
25. R.J. Davey, The effect of impurity adsorption on the kinetics of crystal growth from solution, J. Cryst. Growth 34 (1976) 109-119.
26. P.G. Kowtsoukos, G.H. Nancollas, Influence of strontium ions on the crystallization of hydroxylapatite from aqueous solution, J. Phys. Chem. 85 (1981) 2403-2408.
27. G.H. Nancollas, K. Sawada, Formation of calcium carbonate polymorphs: the influence of magnesium ions and inhibitors, J. Pet. Tech. 1982, 645-652.
28. S. Sarig, A. Glasner, J.A. Epstein, Crystal habit modifiers, J. Cryst. Growth 28 (1975) 295-299.
29. S. Sarig, F. Kahana, On the association between sparingly soluble carbonates and polyelectrolytes, J. Cryst. Growth 35 (1976) 145-152.
30. N. Eidelman, R. Azoury, S. Sarig, Reversal of trends in impurity effects on crystallization parameters, J. Cryst. Growth 74 (1986) 1-9.
31. A.P. Simonelli, S.C. Mehta, W.I. Higuchi, Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone, J. Pharm. Sci. 59 (1970) 633-637.
32. P.J. Reboul, B. Cristau, J.C. Soyfer, 5H-Dibenz[b,f]azepine-5-carboxamide (carbamazepine), Acta Cryst. B37 (1981) 1844-1848.
33. V.L. Himes, A.D. Mighell, W.H. De Camp, Structure of carbamazepine: 5H-dibenz[b,f]azepine-5-carboxamide, Acta Cryst. B37 (1981) 2242-2245.